Anxiety Medical Cannabis Studies


• addiction (10)

• alzheimers/dementia (14)

• amyotrophic-lateral-sclerosis-als-lou-gehrigs (2)

• antibacterial (6)

• antioxidant (8)

• antiprion (1)

• anxiety (10)

• appetite (4)

• arthritis (4)

• asthma (1)

• attention-deficit-hyperactivity-disorder-adhd (5)

• autism (11)

• autoimmune (3)


• batten-disease (6)

• benefits (9)

• breast-cancer (7)


• cancer (94)

• cannabidiol-cbd (8)

• cardiovascular (8)

• cb1-receptor (8)

• cb2-receptor (9)

• cellular-function (4)

• cerebral-palsy (1)

• cognition (2)

• colon-cancer (8)


• d9-tetrahydrocannabinol-thc (4)

• d9-tetrahydrocannabinolic-acid-thca (1)

• diabetes (4)

• drug-interactions (2)


• emesis (6)

• endocannabinoid-system-ecs (45)

• endocrine-system (3)

• epilepsy (30)


• fibromyalgia (2)

• fibrosis (1)


• gastrointestinal-disease (6)

• general (20)

• glaucoma (1)

• glioblastoma (1)

• glioma (9)


• health-care (1)

• hiv (7)

• huntingtons-disease (1)


• immune-function (8)

• infant-development (1)

• inflammation (9)

• ischemia (3)


• krabbe-disease (4)


• liver (2)

• lung-cancer (2)

• lupus (1)


• memory (3)

• mental-illness (14)

• migraine (1)

• mitochondria (1)

• multiple-sclerosis (15)


• national-institute-on-drug-abuse-nida (1)

• nausea (1)

• nervous-system (4)

• neuro-protective-and-neuro-generative (7)


• pain (29)

• pancreatitis (1)

• prostate-cancer (2)


• schizophrenia (2)

• skin (1)

• sports (3)


• thc (1)

• therapeutic (1)

• traumatic-brain-injury-tbi (1)

• View All (505)
  • Action of Cannabidiol on the Anxiety and Other Effects Produced by D9-THC in Normal Subjects (1982)

    It was verified that cannabidiol blocks anxiety caused by D9-tetrahydrocannabinol, in addition to blocking other effects similar to those of marijuana. The results of this study suggest that the effects of cannabidiol, unlike the effects of D9-tetrahydrocannabinol, could be involved in the antagonism of the effects between the two cannabinoids. View study

  • Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa (2014)

    Cannabidiol (CBD) is a non-psychotomimetic component of Cannabis sativa with great psychiatric potential, which includes its use as an antidepressant and anxiolytic compound. Studies with animal models, which perform a myriad of experiments, suggest that CBD exhibited anxiety and antidepressant effects. View study

  • Cannabidiol in Anxiety and Sleep: A Large Case Series. (2019)

    The objective of the present study was to determine if cannabidiol (CBD) helps to improve sleep and / or anxiety in a clinical population. It was concluded that cannabidiol may be beneficial for anxiety-related disorders. Controlled clinical studies are needed. View study

  • Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug (2011)

    The results of these studies showed that cannabidiol (CBD) reduces anxiety in patients with anxiety disorders. studies can be justified in the future with new medical trials with patients with different anxiety disorders. View study

  • Cannabinoid-related agents in the treatment of anxiety disorders- current knowledge and future perspectives (2013)

    In this article we review the evidence that cannabis products have different effects on the regulation of emotions. It has been mentioned that tetrahydrocannabinol (THC) and other herbal, synthetic and endogenous cannabinoids can decrease or increase the behaviors related to fear and anxiety in humans and animals used in experiments. The difference in responses in each individual is due to several genetic and environmental factors and to THC concentrations within the plant. View study

  • Chronic blockade of cannabinoid CB2 receptors induces anxiolytic-like actions associated with alterations in GABA(A) receptors (2011)

    This study supports the key role of CB2 receptors in the regulation of anxiety and, in addition, the effectiveness of the AM630 receptor antagonist further strengthens the potential of CB2 for the treatment of anxiety-related disorders. View study

  • Effects of Cannabidiol (CBD) on Regional Cerebral Blood (2003)

    The evaluation of brain regions in which the anxiolytic effects of CBD were predicted early revealed two groups of voxel of uptake of ECD significantly decreased in the CBD in correspondence with the placebo condition (po0.001, uncorrected for multiple comparisons). In addition there was a set of higher activity with CBD than placebo in the left parahipocampic gyrus (po0.001). These results suggest that CBD has anxiolytic properties and that these effects are mediated by an action in areas of the limbic and paralimbic brain. View study

  • Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? (2017)

    Anxiety and related disorders are the most common mental conditions that affect people in North America. Cannabis is commonly seen as a natural alternative to a variety of medical and mental health conditions. The purpose of this article is to provide a comprehensive review of the current literature on the treatment of cannabis and to identify the potential of cannabis as a therapeutic intervention for anxiety, mood and related disorders. View study

  • Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report ()

    Studies in animals and humans indicate that cannabidiol (CBD), an important component of cannabis, has anxiolytic properties. So far no studies have been conducted related to the effects of this compound on human pathological anxiety and its underlying brain mechanisms. The objective of this study was to investigate patients with generalized social anxiety disorders (SAD) using functional neuroimaging. View study

  • Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice (2011)

    In this research, the aim is to evaluate the anxiolytic effects of alprazolam in different tests using mice. The results show that the increase in the expression of CB2r significantly reduced anxiety-related behaviors, modified the stress response and affected the action of anxiolytic drugs. View study